Arcturus Therapeutics Announces New COVID-19 sa-mRNA Results
Portfolio Pulse from Benzinga Newsdesk
Arcturus Therapeutics announced new results for its sa-mRNA COVID-19 vaccine, showing superior immunogenicity to the Omicron BA.4/5 variant and a longer duration of immune response compared to first-generation mRNA vaccines. This follows the vaccine's approval in Japan in November 2023.

February 05, 2024 | 1:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arcturus Therapeutics' new sa-mRNA COVID-19 vaccine data demonstrates superior immunogenicity to Omicron BA.4/5 and longer immune response, following its recent approval in Japan.
The announcement of superior immunogenicity and longer duration of immune response of Arcturus Therapeutics' sa-mRNA COVID-19 vaccine compared to first-generation mRNA vaccines, coupled with its recent regulatory approval in Japan, is likely to positively impact investor sentiment. This could lead to increased investor confidence in ARCT's product pipeline and potential revenue growth from the vaccine, thus potentially driving the stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100